Latest period
$12.04B
YoY change
-23.8%
5Y CAGR
-3.0%
Peak year (2017)
$41.68B
Latest annual
$9.13B
Cash on Hand history chart for Amgen (AMGN) from 1985 to 2025
Latest: $9.13B
Cash on Hand growth chart for Amgen (AMGN) from 1985 to 2025
Latest: -23.8%
Cash on Hand history table for Amgen (AMGN) from 1985 to 2025
| 2025 | $9.13B | -23.8% | −$2.84B | ||
| 2024 | $11.97B | +9.4% | +$1.03B | ||
| 2023 | $10.94B | +17.6% | +$1.64B | ||
| 2022 | $9.30B | +15.8% | +$1.27B | ||
| 2021 | $8.04B | -24.5% | −$2.61B | ||
| 2020 | $10.65B | +19.5% | +$1.74B | ||
| 2019 | $8.91B | -69.6% | −$20.39B | ||
| 2018 | $29.30B | -29.7% | −$12.37B | ||
| 2017 | $41.68B | +9.4% | +$3.59B | ||
| 2016 | $38.09B | +21.4% | +$6.70B | ||
| 2015 | $31.38B | +16.1% | +$4.36B | ||
| 2014 | $27.03B | +39.3% | +$7.63B | ||
| 2013 | $19.40B | -19.4% | −$4.66B | ||
| 2012 | $24.06B | +16.6% | +$3.42B | ||
| 2011 | $20.64B | +18.5% | +$3.22B | ||
| 2010 | $17.42B | +29.6% | +$3.98B | ||
| 2009 | $13.44B | +40.7% | +$3.89B | ||
| 2008 | $9.55B | +33.6% | +$2.40B | ||
| 2007 | $7.15B | +13.9% | +$874.00M | ||
| 2006 | $6.28B | +19.4% | +$1.02B | ||
| 2005 | $5.25B | -9.5% | −$553.00M | ||
| 2004 | $5.81B | +13.4% | +$685.00M | ||
| 2003 | $5.12B | +9.8% | +$459.00M | ||
| 2002 | $4.66B | +75.2% | +$2.00B | ||
| 2001 | $2.66B | +31.3% | +$634.10M | ||
| 2000 | $2.03B | +52.1% | +$695.10M | ||
| 1999 | $1.33B | +562.9% | +$1.13B | ||
| 1998 | $201.10M | -15.9% | −$38.00M | ||
| 1997 | $239.10M | +41.2% | +$69.80M | ||
| 1996 | $169.30M | +153.8% | +$102.60M | ||
| 1995 | $66.70M | -68.4% | −$144.60M | ||
| 1994 | $211.30M | +64.4% | +$82.80M | ||
| 1993 | $128.50M | +39.7% | +$36.50M | ||
| 1992 | $92.00M | -37.2% | −$54.50M | ||
| 1991 | $146.50M | +310.4% | +$110.80M | ||
| 1990 | $35.70M | — | — | ||
| 1988 | $20.70M | -80.4% | −$84.90M | ||
| 1987 | $105.60M | +83.3% | +$48.00M | ||
| 1986 | $57.60M | -13.5% | −$9.00M | ||
| 1985 | $66.60M | — | — |
- 2025$9.13B-23.8%
- 2024$11.97B+9.4%
- 2023$10.94B+17.6%
- 2022$9.30B+15.8%
- 2021$8.04B-24.5%
- 2020$10.65B+19.5%
- 2019$8.91B-69.6%
- 2018$29.30B-29.7%
- 2017$41.68B+9.4%
- 2016$38.09B+21.4%
- 2015$31.38B+16.1%
- 2014$27.03B+39.3%
- 2013$19.40B-19.4%
- 2012$24.06B+16.6%
- 2011$20.64B+18.5%
- 2010$17.42B+29.6%
- 2009$13.44B+40.7%
- 2008$9.55B+33.6%
- 2007$7.15B+13.9%
- 2006$6.28B+19.4%
- 2005$5.25B-9.5%
- 2004$5.81B+13.4%
- 2003$5.12B+9.8%
- 2002$4.66B+75.2%
- 2001$2.66B+31.3%
- 2000$2.03B+52.1%
- 1999$1.33B+562.9%
- 1998$201.10M-15.9%
- 1997$239.10M+41.2%
- 1996$169.30M+153.8%
- 1995$66.70M-68.4%
- 1994$211.30M+64.4%
- 1993$128.50M+39.7%
- 1992$92.00M-37.2%
- 1991$146.50M+310.4%
- 1990$35.70M—
- 1988$20.70M-80.4%
- 1987$105.60M+83.3%
- 1986$57.60M-13.5%
- 1985$66.60M—
Cash on Hand values are taken from Amgen's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Cash on Hand at Amgen (AMGN)
According to Amgen's latest reported financial statements, the company's latest reported cash and short-term investments is $12.04B. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual cash and short-term investments for Amgen (AMGN) came in at $9.13B – declined 23.8% year-over-year.
Over 2020–2025 (5 years), Amgen cash and short-term investments expanded at a -3.0% compound annual rate, with a net decline across the window.
Amgen cash and short-term investments peaked at $41.68B in 2017; the latest annual figure is $9.13B in 2025 (78.1% below peak).
2017 marks the peak cash and short-term investments at $41.68B, with the historical low of $20.70M recorded in 1988.
Amgen Cash on Hand by Year
Amgen Cash on Hand 2025: $9.13B
Amgen cash and short-term investments in 2025 was $9.13B, declined 23.8% below 2024.
Amgen Cash on Hand 2024: $11.97B
2024's cash and short-term investments for Amgen came in at $11.97B, grew 9.4% from 2023.
Amgen Cash on Hand 2023: $10.94B
Amgen posted cash and short-term investments of $10.94B in 2023, grew 17.6% from 2022.
Amgen Cash on Hand 2022: $9.30B
In 2022, Amgen reported cash and short-term investments of $9.30B, grew 15.8% from 2021.
Amgen Cash on Hand 2021: $8.04B
Amgen cash and short-term investments in 2021 was $8.04B.
See more financial history for Amgen (AMGN).
Sector peers by Cash on Hand
Healthcare peers of Amgen (AMGN), ranked by their latest cash and short-term investments
| $28.12B | |
| $20.10B | |
| $14.56B | |
| $10.11B | |
| $7.27B | |
| $5.74B | |
| $5.26B | |
| $4.24B |
- $28.12B
- $20.10B
- $14.56B
- $7.27B
- $5.74B
- $5.26B
- $4.24B
Frequently asked questions
Amgen (AMGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation